Alvotech SA has announced the acquisition of Xbrane Biopharma AB's R&D operations located at the Karolinska life-science hub in Sweden. This strategic move is part of Alvotech's plans to expand its research and development capabilities and to solidify its presence in the Swedish life-science sector. The transaction has received approval from Xbrane's shareholders and necessary foreign direct investment authorities, with the closing expected in early June 2025. This acquisition will integrate Xbrane's workforce of experienced biosimilar developers into Alvotech, enhancing the company's scientific and innovation capabilities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.